Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07NYF
|
||||
Former ID |
DIB005893
|
||||
Drug Name |
MLN-2201
|
||||
Synonyms |
LDP-01; MLN-01; Anti-beta2-integrin MAb, LeukoSite
|
||||
Drug Type |
Antibody
|
||||
Indication | Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] | Discontinued in Phase 1 | [546763] | ||
Company |
LeukoSite Inc
|
||||
CAS Number |
CAS 339164-13-5
|
||||
Target and Pathway | |||||
Target(s) | Integrin beta-2 | Target Info | [546764] | ||
KEGG Pathway | Rap1 signaling pathway | ||||
Phagosome | |||||
Hippo signaling pathway | |||||
Cell adhesion molecules (CAMs) | |||||
Natural killer cell mediated cytotoxicity | |||||
Leukocyte transendothelial migration | |||||
Regulation of actin cytoskeleton | |||||
Pertussis | |||||
Legionellosis | |||||
Leishmaniasis | |||||
Malaria | |||||
Amoebiasis | |||||
Staphylococcus aureus infection | |||||
Tuberculosis | |||||
HTLV-I infection | |||||
Rheumatoid arthritis | |||||
Viral myocarditis | |||||
PANTHER Pathway | Integrin signalling pathway | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.